Skip to main content

Table 2 Multiple regression analysis of dietary fiber intake with clinical and laboratory variables

From: Impact of dietary fiber intake on glycemic control, cardiovascular risk factors and chronic kidney disease in Japanese patients with type 2 diabetes mellitus: the Fukuoka Diabetes Registry

Variables

Mean

Regression coefficient

p for trend

Body mass index (kg/m2)

23.8 ± 0.06

−0.18 [−0.24,-0.11]

<0.0001

Waist circumference (cm)

85.9 ± 0.2

−0.56 [−0.73,-0.39]

<0.0001

Fasting plasma glucose (mmol/l)

7.73 ± 0.03

−0.049 [−0.084,-0.014]

0.007

HbA1c (%)

7.42 ± 0.02

−0.022 [−0.038,-0.005]

0.009

HbA1c (mmol/mol)

57.6 ± 0.2

−0.24 [−0.42,-0.06]

0.009

Fasting serum C-peptide (nmol/l)

0.402 ± 0.003

−0.009 [−0.013,-0.006]

<0.0001

HOMA2%-B

45.7 ± 0.4

−0.26 [−0.68, 0.17]

ns

HOMA2%-S

106.0 ± 0.6

1.95 [1.27, 2.62]

<0.0001

Adiponectin (μg/ml)*

9.1 [8.9-9.2]

0.006 [−0.003, 0.016]

ns

HS-CRP (mg/l)*

0.50 [0.48-0.52]

−0.067 [−0.090,-0.043]

<0.0001

Total cholesterol (mmol/l)

4.99 ± 0.01

0.009 [−0.005, 0.023]

ns

LDL cholesterol (mmol/l)

2.87 ± 0.01

0.010 [−0.002, 0.022]

ns

HDL cholesterol (mmol/l)

1.47 ± 0.01

0.008 [0.001, 0.014]

0.017

Triglyceride (mmol/l)*

1.22 [1.20-1.24]

−0.013 [−0.022,-0.005]

0.003

Systolic blood pressure (mmHg)

130.7 ± 0.3

−0.35 [−0.64,-0.06]

0.017

Diastolic blood pressure (mmHg)

74.7 ± 0.2

−0.05 [−0.22, 0.13]

ns

Urinary albumin excretion (mg/g)

28.2 [26.8-29.7]

−0.092 [−0.121,-0.063]

<0.0001

eGFR (ml/min/1.73 m2)

75.0 ± 0.3

0.34 [0.01, 0.67]

0.042

  1. Mean ± SE. *Geometric means with 95% CI in brackets. HOMA2-%B, homeostasis model assessment β-cell function; HOMA2-%S, homeostasis model assessment insulin sensitivity; HS-CRP, high sensitivity-C reactive protein; eGFR, estimated glomerular filtration rate. The multivariate adjustment included age, sex, duration of diabetes, current smoking habits, current drinking habits, total energy intake, fat intake, saturated fatty acid intake, protein intake (only for urinary albumin excretion and eGFR), leisure time physical activity and use of oral hypoglycemic agents or insulin.